Whey Protein Concentrate 40% Made of Milk of Immunized Cows to Aid in the Prevention of Relapse of Clostridium Difficile-Diarrhea
This study has been terminated.
(Study is completed and analysis completed)
Sponsor:
University of Pittsburgh
Collaborator:
MucoVax, BV, the Netherlands
Information provided by:
University of Pittsburgh
ClinicalTrials.gov Identifier:
NCT00177775
First received: September 13, 2005
Last updated: December 16, 2008
Last verified: December 2008
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The primary objective of this study is to assess the safety of the investigational agent, MucoMilk®, a polyclonal-antibody enriched Whey Protein Concentrate 40% (WPC-40) made of milk of immunized cows. Secondary objectives will investigate the effectiveness of MucoMilk® as an aid in the prevention of relapse of C. difficile-associated diarrhea (CDAD).
| Condition | Intervention | Phase |
|---|---|---|
|
Positive C-Diff Culture |
Drug: MucoMilk product |
Phase 2 Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Factorial Assignment Masking: Open Label Primary Purpose: Prevention |
| Official Title: | Whey Protein Concentrate 40% (WPC-40) Made of Milk of Immunized Cows to Aid in the Prevention of Relapse of Clostridium Difficile-Diarrhea: A Prospective, Randomized, Controlled Phase II Study - Version 5.1.B |
Resource links provided by NLM:
Further study details as provided by University of Pittsburgh:
Primary Outcome Measures:
- To investigate the effectiveness of MucoMilk®
Secondary Outcome Measures:
- To assess the safety of MucoMilk
| Estimated Enrollment: | 60 |
| Study Start Date: | April 2005 |
| Estimated Study Completion Date: | August 2005 |
Show Detailed Description
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
Eligible subjects must meet all of the following inclusion criteria:
- Willingness and ability to comply with all study requirements, to fully understand all elements of informed consent, and to provide written informed consent.
- Confirmed CDAD by ELISA toxin assay or cell test.
- Are currently receiving or have received standard antibiotic treatment for CDAD with oral/intravenous metronidazole and/or vancomycin for a minimum of 10 days per standard of care at the discretion of the study physician.
- Resolution of diarrhea to a maximum of 3 stools per day following completion of antibiotic therapy.
- Ability to tolerate fluids by mouth or by feeding tube.
- Have passage of stools.
Exclusion Criteria:
Subjects will not be eligible to participate in this study if any of the following exclusion criteria apply:
- Unable to provide informed consent.
- History of lactose intolerance.
- Cannot tolerate fluids by mouth or by feeding tube, or are judged by the attending physician unfit to receive fluids by mouth or by feeding tube.
- Have received an investigational drug within 4 weeks prior to study entry.
- Have underlying gastrointestinal tract disease characterized by diarrhea or unformed stools.
- Are currently receiving any antidiarrheal medications.
- Current use of an ileostomy or colostomy.
- History of milk allergy.
- Current use of Saccharomyces boulardii, Lactinex, or Culturelle preparations at start of study. (S. boulardii is a non-colonizing yeast species purported to support gastrointestinal tract function. It has been widely studied and used to help prevent post-antibiotic diarrhea.)
- Reside outside of the United States.
- Cannot speak or read English.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00177775
Locations
| United States, Pennsylvania | |
| University of Pittsburgh Medical Center | |
| Pittsburgh, Pennsylvania, United States, 15213 | |
Sponsors and Collaborators
University of Pittsburgh
MucoVax, BV, the Netherlands
Investigators
| Principal Investigator: | Peter Veldkamp, MD | University of Pittsburgh |
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00177775 History of Changes |
| Other Study ID Numbers: | IRB# 0412033 |
| Study First Received: | September 13, 2005 |
| Last Updated: | December 16, 2008 |
| Health Authority: | United States: Institutional Review Board |
Additional relevant MeSH terms:
|
Diarrhea Signs and Symptoms, Digestive Signs and Symptoms |
ClinicalTrials.gov processed this record on May 23, 2013